Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
melanoma
Pharma
Huyabio's HDAC inhibitor scores in phase 3 melanoma study
Huyabio's HDAC inhibitor HBI-8000 has succeeded in combo with Bristol Myers Squibb’s Opdivo in a phase 3 trial of patients with advanced skin cancer.
Kevin Dunleavy
Jul 14, 2026 10:48am
Fierce Biotech
Shedding 60% of workforce, Replimune vows to continue operations
Apr 21, 2026 2:15am
Fierce Biotech
Replimune to lay off staff after 'disappointing' second rejection
Apr 10, 2026 1:56pm
ASCO: Bristol CMO brushes off LAG-3 concern after melanoma flop
Jun 3, 2025 8:00am
BMS’ Opdualag flunks trial as adjuvant for resected melanoma
Feb 14, 2025 8:15am
Ideaya hires Gilead leader to head up commercialization push
Nov 19, 2024 10:34am
